{"id":"sys6006","rwe":[{"pmid":"39364147","year":"2024","title":"Safety and immunogenicity of a SARS-CoV-2 mRNA vaccine (SYS6006) in minks, cats, blue foxes, and raccoon dogs.","finding":"","journal":"Frontiers in cellular and infection microbiology","studyType":"Clinical Study"},{"pmid":"38860446","year":"2024","title":"The safety, immunogenicity, and efficacy of heterologous boosting with a SARS-CoV-2 mRNA vaccine (SYS6006) in Chinese participants aged 18 years or more: a randomized, open-label, active-controlled phase 3 trial.","finding":"","journal":"Emerging microbes & infections","studyType":"Clinical Study"},{"pmid":"38506170","year":"2024","title":"Long-term immunogenicity and safety of heterologous boosting with a SARS-CoV-2 mRNA vaccine (SYS6006) in Chinese participants who had received two or three doses of inactivated vaccine.","finding":"","journal":"Journal of medical virology","studyType":"Clinical Study"},{"pmid":"38461050","year":"2024","title":"Safety and immunogenicity of heterologous boosting with a bivalent SARS-CoV-2 mRNA vaccine (XBB.1.5/BQ.1) in Chinese participants aged 18 years or more: A randomised, double-blinded, active-controlled phase 1 trial.","finding":"","journal":"Vaccine","studyType":"Clinical Study"},{"pmid":"38365485","year":"2024","title":"Immunogenicity and safety of a SARS-CoV-2 mRNA vaccine (SYS6006) in healthy Chinese participants: A randomized, observer-blinded, placebo-controlled phase 2 clinical trial.","finding":"","journal":"Vaccine","studyType":"Clinical Study"}],"tags":[{"label":"Small Molecule","category":"modality"},{"label":"Active","category":"status"},{"label":"Jiangsu Province Centers for Disease Control and Prevention","category":"company"}],"phase":"marketed","safety":{},"trials":[],"aliases":[],"company":"Jiangsu Province Centers for Disease Control and Prevention","patents":[],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=SYS6006","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T01:02:09.316003+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T01:02:16.082604+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=SYS6006","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T01:02:16.835793+00:00"}},"allNames":["sys6006"],"offLabel":[],"synonyms":[],"timeline":[],"approvals":[],"ecosystem":[],"mechanism":{"modality":"Small Molecule","explanation":"","oneSentence":"","technicalDetail":"sys6006 is a small molecule that binds to a specific protein or receptor, triggering a downstream signaling cascade that ultimately leads to a therapeutic effect. The exact mechanism of action is not well understood and requires further research."},"commercial":{},"references":[{"id":1,"url":"https://clinicaltrials.gov/search?intr=sys6006","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":2,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=sys6006","fields":["publications"],"source":"PubMed/NCBI"}],"_enrichedAt":"2026-03-31T10:17:31.952246","_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T01:02:19.104086+00:00","fieldsConflicting":1,"overallConfidence":0.8},"biosimilars":[],"competitors":[],"genericName":"sys6006","indications":{"approved":[],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT05354063","phase":"PHASE1","title":"A Study of SARS-CoV-2 mRNA Vaccine (SYS6006) in Chinese Healthy Older Adults.","status":"UNKNOWN","sponsor":"CSPC ZhongQi Pharmaceutical Technology Co., Ltd.","startDate":"2022-06-01","conditions":["SARS-CoV-2"],"enrollment":40,"completionDate":"2023-10-01"},{"nctId":"NCT05439824","phase":"PHASE2","title":"A Study of SARS-CoV-2 mRNA Vaccine (SYS6006) in Chinese Healthy Participants Aged 18 Years or More","status":"UNKNOWN","sponsor":"CSPC ZhongQi Pharmaceutical Technology Co., Ltd.","startDate":"2022-06-28","conditions":["SARS-CoV-2 Infection"],"enrollment":450,"completionDate":"2023-06-28"},{"nctId":"NCT05354089","phase":"PHASE1","title":"A Study of SARS-CoV-2 mRNA Vaccine (SYS6006) in Chinese Healthy Adults Aged 18 -59 Years.","status":"UNKNOWN","sponsor":"CSPC ZhongQi Pharmaceutical Technology Co., Ltd.","startDate":"2022-04-27","conditions":["SARS-CoV-2"],"enrollment":40,"completionDate":"2023-10-01"},{"nctId":"NCT05855408","phase":"PHASE4","title":"Effectiveness of a Second COVID-19 Vaccine Booster in Chinese Adults","status":"UNKNOWN","sponsor":"Jiangsu Province Centers for Disease Control and Prevention","startDate":"2023-05-18","conditions":["COVID-19"],"enrollment":10000,"completionDate":"2024-12-31"},{"nctId":"NCT05492643","phase":"NA","title":"The Safety and Immunogenicity of SARS-CoV-2 mRNA Vaccine (SYS6006) as Heterologous Booster in Participants Aged 18 Years and Older Vaccinated With Inactivated SARS-CoV-2 Vaccine","status":"UNKNOWN","sponsor":"Zhongnan Hospital","startDate":"2022-08-13","conditions":["SARS-CoV-2","Safety","Immunotoxicity"],"enrollment":1000,"completionDate":"2023-03-01"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"formularyStatus":[],"_enricherVersion":"v2-openfda","developmentCodes":[],"ownershipHistory":[{"period":"","companyName":"Jiangsu Province Centers for Disease Control and Prevention","relationship":"Original Developer"}],"publicationCount":8,"therapeuticAreas":["Oncology"],"biosimilarFilings":[],"originalDeveloper":"Jiangsu Province Centers for Disease Control and Prevention","recentPublications":[{"date":"2024","pmid":"39364147","title":"Safety and immunogenicity of a SARS-CoV-2 mRNA vaccine (SYS6006) in minks, cats, blue foxes, and raccoon dogs.","journal":"Frontiers in cellular and infection microbiology"},{"date":"2024 Dec","pmid":"38860446","title":"The safety, immunogenicity, and efficacy of heterologous boosting with a SARS-CoV-2 mRNA vaccine (SYS6006) in Chinese participants aged 18 years or more: a randomized, open-label, active-controlled phase 3 trial.","journal":"Emerging microbes & infections"},{"date":"2024 Mar","pmid":"38506170","title":"Long-term immunogenicity and safety of heterologous boosting with a SARS-CoV-2 mRNA vaccine (SYS6006) in Chinese participants who had received two or three doses of inactivated vaccine.","journal":"Journal of medical virology"},{"date":"2024 Apr 2","pmid":"38461050","title":"Safety and immunogenicity of heterologous boosting with a bivalent SARS-CoV-2 mRNA vaccine (XBB.1.5/BQ.1) in Chinese participants aged 18 years or more: A randomised, double-blinded, active-controlled phase 1 trial.","journal":"Vaccine"},{"date":"2024 Mar 7","pmid":"38365485","title":"Immunogenicity and safety of a SARS-CoV-2 mRNA vaccine (SYS6006) in healthy Chinese participants: A randomized, observer-blinded, placebo-controlled phase 2 clinical trial.","journal":"Vaccine"}],"companionDiagnostics":[],"genericManufacturerList":[],"status":"active","brandName":"SYS6006","companyName":"Jiangsu Province Centers for Disease Control and Prevention","companyId":"jiangsu-province-centers-for-disease-control-and-prevention","modality":"Biologic","firstApprovalDate":"","aiSummary":"","enrichmentLevel":3,"visitCount":1,"regulatoryByCountry":[{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":0,"withResults":0},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T01:02:19.104086+00:00","fieldsConflicting":1,"overallConfidence":0.8},"verificationStatus":"enriching","dataCompleteness":{"mechanism":false,"indications":false,"safety":false,"trials":true,"score":1}}